Bristol Myers Squibb accelerates drug development pipeline with Accenture GenAI

Bristol Myers Squibb's drug development pipeline faced increasing complexity and timelines, with researchers spending significant time on literature review, data synthesis, and regulatory document preparation rather than scientific discovery.

BMS partnered with Accenture to deploy generative AI across drug development workflows, using large language models to accelerate literature review, synthesize research findings, generate regulatory documentation, and support clinical trial design decisions.

The generative AI deployment accelerated multiple stages of the drug development pipeline, enabling researchers to synthesize relevant literature and generate insights significantly faster. The partnership established a scalable framework for enterprise GenAI adoption across pharmaceutical R&D.